Genomics Market Revenue, Diagnostic Testing Volume, Adoption Rates, Pricing Metrics, Supply Chain Performance, Market Share Analysis, and Innovation Trends

Revenue, 2025

USD 44.21

Forecast Year, 2035

USD 185.57

CAGR, 2026 - 2035

15%

Report Coverage

Global

What is the Genomics Market Size?

The global genomics market size was estimated at USD 44.21 billion in 2025 and is anticipated to reach around USD 185.57 billion by 2035, expanding at a CAGR of 15% from 2025 to 2034. The rising demand in the genomics market is observed owing to having a better understanding of the evolution and to protect the biological ecosystem which helps in the development of new diagnostics, therapeutics, and vaccines.

Genomics Market Key Takeaways

• North America dominated the global genomics market with the largest market share of 42.65% in 2025.
• Asia Pacific is expected to expand at a solid CAGR of 18.11% during the forecast period.
• By component type, the consumables segment contributed the largest market share of 40% in 2025.
• By technology, the PCR segment has held the major market share in 2025.
• By application, the diagnostics segment dominated the market in 2025.
• By end-users, the research centers and academic and government institutes segment led the market in 2025.

How Artificial Intelligence (AI) is Changing Genomics Industry?

Integration of artificial intelligence and machine learning in genomics is essential due to the increasing number of DNA sequencing and other biological techniques along with the complexity of the data sets, AL/ML-based computation tools facilitate handling, extracting, and interpreting valuable information. Researchers are benefiting from this integration in programs such as identifying genetic disorders, identifying primary causes of cancer, cancer progress, disease source and improving the function of gene editing. The AI/ML integration helps in predicting and identifying hidden patterns of genomic data. Scientists are using it to predict the future variation of various diseases to help public health.

AI is affecting the genomics market with improvements in speed, accuracy, and scalability through research, patient care, and drug discovery. It can analyze genomic data rapidly while looking for complex patterns and genetic variations, thereby accelerating discoveries and reducing costs. The services offered also include drug development: identifying promising targets, predicting cures, and treatment results. The AI-related personalised medicine then assists in prevention and treatment strategies. Diagnostic accuracy and reliability of genome sequencing, as well as innovations in gene editing, all benefit from AI. AI now helps with individual care and health planning through integrating multi-omic datasets.

Genomics Market Growth Factors

• Increasing government funding in the field of microbiology and genetics is one of the major driving factors promoting the growth of the genomics market.
• Reducing cost of sequencing the human genome further supports the market advancement. As per the NHGRI-funded genome-sequencing groups, the price has fallen from 2015 to 2020 and at present, the cost of generating is below $1,000. It is also seen the average commercial price is much more below than the current prices. Recently, the huge entry of new market players followed by various startups is propelling the growth of the market. For instance, Guardant from the United States of America, Freenom, Allogene Therapeutics, Oxford Nanopore Technologies from the UK are some of the major startups in genomic market.
• Technological advancement leads to rising application of the genome and genomic based material. This factor considered as one of the major driving factors to boost the market adoption. Furthermore, emerging biotech companies and genetic-based startups are playing a huge role in the development of next-generation sequencing technologies. COVID- 19 disorders mainly affect the human lungs and responsible for the number of fatalities around the world. In order to control or protect the patients, the study performed by the University of Minnesota describing the role of genetic for the treatment of the COVID-19 patients. The major founding of the test is to effect of abacavir treatment in HIV patients. Genomic test also helps to determine the adverse effect risk on individual patients.
• The unhealthy aging of the individuals following with increasing trend of precision medicine will be the most attractive opportunity for the growth of the market. However, high investment cost is also one of the major restraining factors which affect the growth of the market. Further, limited number of skilled professionals across the world is the major challenge faced by the industry today.

Market Scope

Market Dynamics

Market Drivers

Increasing adoption of genomics in drug discovery and development

Researchers analyze the amount of genomics data with the advancement of genomic technologies to identify disease-associated genes, understand disease mechanisms, and develop targeted therapies. Genomics plays a crucial role by helping to accelerate the drug discovery process by enabling researchers to identify and prioritize drug targets based on genomic data, which leads to more efficient and effective drug development. Genomic information is used to identify genetic mutations, gene expression patterns, and other molecular markers associated with diseases, allowing for the identification of novel drug targets and the development of precision therapies tailored to an individual's genomic profile. In addition, genomics is being utilized in clinical trials to stratify patients based on their genomic profile and optimize treatment strategies. Genomic data is used to identify patient populations that are more likely to respond to a particular drug, leading to more targeted and personalized treatment approaches. This has the potential to improve patient outcomes, reduce adverse effects, and increase the success rate of clinical trials.

Moreover, the use of genomics in pharmacogenomics, which involves studying how individuals' genes affect their response to drugs, is gaining momentum. Pharmacogenomic testing provides insights into an individual's genetic variations that impact drug metabolism, efficacy, and safety, helping to guide personalized medication dosing and selection. This improves patient outcomes by reducing adverse drug reactions, optimizing drug selection, and minimizing trial-and-error approaches in drug prescribing.

Technology Advancement

The field of genomics has witnessed significant advancements in technology in recent years, with notable breakthroughs such as the revolutionary CRISPR technology, which allows for precise editing of DNA by adding, removing, or altering specific sections of the genome. CRISPR employs an enzyme that cuts DNA at targeted locations, guided by a small RNA molecule. In addition to CRISPR, other technological advancements have greatly simplified and facilitated data-related operations critical to genomics research. Cloud technology and composable infrastructure, for instance, have been widely adopted for data storage, analysis, and manipulation, streamlining data interactions and speeding up research results. Rapid research outcomes enable scientists to accelerate the development of new therapeutic approaches.

In addition, Nanotechnology is also a significant advancement in genomics research, with potential applications in the development of genetically modified organisms (GMOs) and overcoming existing constraints. Nanotechnology has the potential to enhance biotransformation processes and improve the production of genetically engineered plants, among other applications. Furthermore, nanotechnology offers opportunities for coordinated management strategies in diverse areas, including agriculture, thereby reducing uncertainties and expanding possibilities in genomics research.

Market Restraint

Cost and Affordability

Despite advancements in DNA sequencing technologies, genomic testing and analysis are expensive, particularly for whole genome sequencing and comprehensive genomic profiling. The high costs associated with genomic testing and interpretation are a restraint on the widespread adoption of genomics in clinical practice, especially in resource-limited settings or for individuals with limited financial resources. Cost considerations also impact the availability and accessibility of genomic products and services, which hinders the growth of the genomics market.

Market Opportunities

Precision Medicine

Precision medicine involves tailoring medical treatments and interventions based on an individual's genomic information, allowing for personalized and targeted healthcare. As the understanding of the human genome continues to advance, there are increasing opportunities for genomics to play a pivotal role in guiding treatment decisions, optimizing patient outcomes, and reducing healthcare costs. The integration of genomics into precision medicine workflows presents a significant growth opportunity for the genomics market.

Expansion of Genomics in Emerging Markets

While genomics has gained significant traction in developed markets, there is an opportunity for expansion in emerging markets. Emerging markets, such as Asia-Pacific, Latin America, and Middle East & Africa, are witnessing rapid economic growth, improving healthcare infrastructure, and increasing awareness about the benefits of genomics. As a result, there is a growing demand for genomic products and services in these regions, including genetic testing, diagnostics, and personalized medicine. Expanding genomics in emerging markets presents an opportunity for market players to tap into new customer bases and geographical regions and leverage the potential of genomics in diverse populations and healthcare settings.

Segment Insights

Product and Service Insights

Global genomics market is classified on the basis of aspects such as product and services, technology, application, and end-users. The products and services are further classified into consumables, services, and systems and software. The market is mostly dominated by consumables segment contributed the largest market share of 40% in 2024. The common product includes in the consumables are channel pipette, PCR plates, assay kit, assay tubes, centrifuge, and many more. Further, service segment is predicted to grow at the highest rate within the forecast period. Growing keen interest by the professionals and better service availability is considered as one of the major driving factors which encourage the development of the market.

Technology Type Insight

The technology-based market of the genome is classified into sequencing, PCR, Microarray, and others. PCR is a widely used method in the industry. The test used in the lab to prepare a number of copies for the specific DNA. The PCR segment has held the major market share in 2024. Reducing the cost of the cell implication is the prime factor for its importance and growth. High incidence of infectious diseases coupled with PCR technology development is one of the major driving factors which promotes the growth of the market.

Application Type Insight

The diagnostics segment dominated the market in 2024. Diagnostics, drug discovery and development, precision medicine, agriculture, and animal research are few major applications assessed in the genomic market. Research study claims that, diagnostics segment is the fasted growing application in the genomic market and it is expected to mirror this trend during years to come. Decreasing cost in the diagnostic segment is the pointing factor to spur the growth of the market. Furthermore, increasing research and development in genomics assist in synergies the sales of the genomic based product and services.

End-Users Type Insight

In terms of end-users, the market is classified into research centers and academic pharmaceutical and biotechnology companies, hospitals & clinics, and other end users. The research centers and academic and government institutes segment led the market in 2024. The largest end-users hold more than half of the global market shares. Increasing practical applicability in academics is boosting the growth of the market.

Regional Insights

Why Does North America Lead the Genomics Market?

The region is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East, and Africa. Amongst all, North America dominated the global genomics market with the largest market share of 42.65% in 2024. In the same region, the U.S. itself captures more than 80% of the market shares. U.S. shows presence of around 70% of startups in the genomic market. Government guidelines following reimbursement policies are the major factor that illuminating the growth of the market in the region.

U.S. Genomics Market Size and Growth 2026 to 2035

The U.S. genomics market size was evaluated at USD 14.43 billion in 2025 and is predicted to be worth around USD 58.47 billion by 2035, rising at a CAGR of 15% from 2026 to 2035.

The U.S. Market Trends

The U.S. plays a dominant role within the region, mainly due to its exceptional precision medicine and massive multi-omics database scaling. The NIH's All of Us Research Program has also expanded to include over 747,000 participants, integrating whole-genome sequencing and electronic health records, with a focus heavily on reducing European-ancestry clinical bias, accelerating pharmacogenomics, and returning direct genetic results.

How will Asia Pacific Grow in the Market?

Asia Pacific is anticipated to have the fastest growth during the forecast period, due to an expanding patient base for chronic and genetic diseases and the rapid clinical adoption of next-generation sequencing. National precision medicine programs and funding rollouts across China, India, Japan, and South Korea are expanding local biobanking, sequencing facilities, and bioinformatics. Additionally. Bioinformatics integration and regional adoption of cloud-based analysis and AI-driven platforms to process expanding volumes of genomic data.

India Market Trends

India plays a distinctive role within the region, mainly due to its strong emphasis on genetic diversity mapping and cost-effective indigenous diagnostics. The Genome India Project has sequenced data from 10,000 individuals across 83 populations, and DBT and BIRAC established Bio-AI Mulankur hubs combining gene sequencing with artificial intelligence for structural biology, predictive medicine, and localized drug targets.

How will Europe be Considered Notable Growth in the Market?

Europe is experiencing notable growth in the global market, driven mainly by rising chronic disease rates, lower DNA sequencing costs, and government-supported precision medicine initiatives. Increasing precision medicine demand for tailored therapies in oncology and rare diseases. Technological advances lead to the greater adoption of next-generation sequencing with lower costs. Furthermore, national healthcare integration in the UK and France, and data harmonization policies are improving access to health data.

Germany Market Trends

Germany is a key contributor within the region, mainly due to its exceptional anchoring for clinical next-generation sequencing translation in oncology and rare diseases. The genomDE initiative also facilitates a standardized genome sequencing framework linked to the European 1+ Million Genomes project, backed by the Federal Ministry of Education and Research and ELIXIR Germany, with stringent regulations on direct-to-consumer testing to ensure oversight by qualified practitioners.

How will Latin America Grow in the Market?

Latin America is experiencing significant growth in the global market, mainly driven by unique genetic diversity and increasing demands for precision oncology and localized genomic research. Rising disease burden further accelerating adoption of personalized medicine. The Genetics of Latin American Diversity (GLAD) Project aims to enhance genomic research, and the Latin America Genomics Breast Cancer Consortium (LAGENO-BC) aims to study breast cancer predispositions in Latina populations with expanded coordination in genetic testing activities.

Brazil Market Trends

Brazil plays a distinctive role within the region, mainly due to Brazil's government driving genomic advancement through Genomas Brasil, the Brazilian Rare Genomes Project, and industrial integration. Genomas Brasil builds a national genomic database by sequencing 100,000 genomes for diverse groups. The Rare Genomes Project uses whole-genome sequencing in public health centers for rare diagnoses.

How will the Middle East and Africa Grow in the Market?

The Middle East and Africa are experiencing significant growth in the global market. High burden of hereditary and consanguineous genetic disorders, major government-backed national genome initiatives, and economic diversification investments in healthcare infrastructure mainly drive this growth. Landmark efforts like the Saudi Human Genome Program and the Emirati Genome Project have advanced large-scale clinical sequencing. Additionally, national healthcare modernization and economic diversification, shifting away from oil dependence in the Gulf, prioritize advanced molecular diagnostics.

UAE Market Trends

UAE plays a pioneering role within the region, mainly due to stringent government initiatives and policies supporting market expansion in the Middle East. This is further highlighted by the National Genome Strategy to map citizen DNA over 10 years, the Emirati Genome Program utilizing AI to sequence one million genomes for preventive care, and mandatory pre-marital screening laws for early genetic compatibility interventions.

Value Cain Analysis

• R&D: Developmental sciences discover drug compounds and research therapeutic utility. Preclinical standardization will be done to check the safety and efficacy of drugs.
  Key Players: Novartis, Pfizer, Roche, Merck & Co., Johnson & Johnson.
• Clinical Trials and Regulatory Approvals: The systematic testing of new drug candidates in humans and seeking regulatory authority approval, such as the FDA, to market the drug.
  Key Players: Pfizer, Novartis, and AbbVie.
• Formulation and Final Dosage Preparation: With this step, active pharmaceutical ingredients are converted into a well-defined dosage form (e.g., tablet, capsule, or injection) that is stable, effective, and patient-compliant.
  Key Players: Johnson & Johnson, Pfizer, Merck
• Packaging and Serialization: Receiving from the manufacturing unit of the pack drug product and giving Unique Identification to every single unit for tracking and tracing along the supply chain.
  Key Players: Amcor, Gerresheimer AG, Berry Global
• Distribution to Hospitals, Pharmacies: Refers to the distribution and storage of finished drugs, making sure they reach health care providers under the right conditions in time to the patients.
  Key Players: McKesson Corporation, Cencora (formerly AmerisourceBergen), Cardinal Health.
• Patient Support and Genomics Services: It involves the services and support provided to patients, which may be based on genomic data, to improve outcomes from treatment and the well-being of patients in general.
  Key Players: Illumina, Tempus, Foundation Medicine, Guardant Health, Invitae.

Genomics Market Companies

• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Oxford Nanopore Technologies
• QIAGEN N.V.
• BGI
• Eurofins Scientific
• GE Healthcare
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Hoffmann-La Roche Ltd.
• Others

Recent Developments

• In September 2025, Synthesize Bio raised $10 million in a seed round led by Madrona, with participation from Sahsen Ventures, Inner Loop Capital, Point Field Partners, and AI2 Incubator.
  https://www.pharmiweb.com
• In August 2025, MedGenome launched India's first CNS Tumour Methylation Classifier Test, enabling accurate diagnosis of over 90 brain and CNS tumors, facilitating optimal treatment decisions.
  https://www.expresshealthcare.in

Segments Covered in the Report

By Product and Services

• Consumables
• Systems and Software
• Services

By Technology

• PCR (Polymerase Chain Reaction)
• Sequencing
• Microarray
• Nucleic Acid Extraction and Purification
• Other Technologies (Branched DNA Analysis, Single-cell Genomics Analysis, and Flow Cytometry)

By Application

• Drug Discovery and Development
• Diagnostics
• Precision Medicine
• Agriculture and Animal Research
• Other Applications

By End-Users

• Hospitals & Clinics
• Research Centers and Academic & Government Institutes
• Pharmaceutical & Biotechnology Companies
• Other End-users

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa